Callan JMB Inc. has announced the signing of a strategic teaming agreement with Biostax Corp, doing business as Attune Biotech Inc. Under the agreement, Callan JMB will act as an independent third-party overseer for Attune’s manufacturing, quality assurance, and deployment operations. The agreement includes providing federal oversight services such as manufacturing quality assurance, FDA audit readiness, BARDA contract compliance, and Strategic National Stockpile deployment coordination. The partnership is expected to generate approximately $50 to $75 million in total combined revenue over the next five years, with Callan JMB’s share estimated between $25 million and $45 million, depending on contract terms and scope.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Callan JMB Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9626143-en) on January 15, 2026, and is solely responsible for the information contained therein.